Actively Recruiting

Phase 2
Age: 18Years +
All Genders
ID05896293

Kisspeptin Administration Subcutaneously to Patients With Reproductive Disorders

Led by Stephanie B. Seminara, MD · Updated on 2025-10-03

36

Participants Needed

1

Research Sites

N/A

Total Duration

On this page

AI-Summary

What this Trial Is About

Researchers are studying whether kisspeptin, a natural hormone, can stimulate the release of reproductive hormones in men and women with idiopathic hypogonadotropic hypogonadism (IHH). They are also exploring if kisspeptin can help women release eggs from their ovaries. This is a phase 2 clinical trial funded by the FDA Office of Orphan Products Development (OOPD). The trial aims to understand kisspeptin's effects on hormone release and ovarian function in this specific condition. Participants will receive kisspeptin administered subcutaneously through a pump that delivers the hormone in pulses every 60 to 240 minutes for two weeks. Before starting kisspeptin, some participants may receive a single injection of leuprolide acetate about six days earlier. Women will have pelvic ultrasounds to monitor follicle growth, and blood samples will be taken frequently during treatment to measure hormone responses. Optional extended blood sampling sessions may also occur before and after the two-week treatment. During the study, participants will undergo medical history reviews, physical exams, and screening lab tests. Women will have ultrasound scans to track follicular development, and all participants will have blood drawn every 10 minutes during certain sessions to assess luteinizing hormone activity. Researchers will measure changes in hormone pulse amplitude over two weeks and, for women, the presence of mature follicles or ovulation. The total participation timeline includes these assessments alongside kisspeptin administration and follow-up monitoring.

CONDITIONS

Brief Title

Kisspeptin Administration Subcutaneously to Patients With IHH

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Confirmed diagnosis of congenital idiopathic hypogonadotropic hypogonadism (IHH) supported by low sex steroids with low or inappropriately normal gonadotropins
  • Normal blood pressure (systolic below 140 mm Hg and diastolic below 90 mm Hg)
  • No current or recent use of medications that affect the reproductive axis, or willingness to complete appropriate medication washout
  • Adults aged 18 years or older
Not Eligible

You will not qualify if you...

  • Any medical, mental, or behavioral condition likely to interfere with completing the study
  • Excessive alcohol use (more than 10 drinks per week) or active illicit drug use
  • Pregnant, trying to become pregnant, or breastfeeding
  • History of bilateral oophorectomy, breast cancer, thromboembolic disease, coronary artery disease, stroke, thrombophilic disorders, or unexplained abnormal genital bleeding

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person) for medical history review, physical exam, and screening labs

Run-in Period

Duration - Approximately 6 days

Participants may receive a single subcutaneous injection of leuprolide acetate approximately six days before starting kisspeptin treatment.

1 visit (in-person) for injection administration

Treatment

Duration - 2 weeks

Participants receive pulsatile subcutaneous kisspeptin administered by a pump for two weeks.

Approximately 10 sessions of 70-minute blood sampling every 10 minutes and about 4 pelvic ultrasounds for women during treatment

Trial Site Locations

Total: 1 location

1

Massachusetts General Hospital

Boston, Massachusetts, United States, 02114

Actively Recruiting

Loading map...

Research Team

S

Study Coordinator

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

OTHER

Number of Arms

1

Similar Trials

Assessment of Endometrial Thickness Among Adolescent and You...

Primary Ovarian Insufficiency

Actively Recruiting

1 location

The Genetics of Neuroendocrine Reproductive Disorders and of...

Kallmann Syndrome

Actively Recruiting

1 location

Kisspeptin Administration Subcutaneously to Patients With Hy...

Hypothalamic Amenorrhea

Actively Recruiting

1 location

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here